Dr David Deaton joins Endovab

Dr David Deaton is the former Chief of Vascular and Endovascular surgery at Georgetown University Hospital and was most recently a staff vascular surgeon at the Cleveland Clinic.   Currently he is the chief medical officer at Syntactx, a clinical research organization, in New York in addition to a variety of consulting positions for start-up and established medical device firms. Dr Deaton has a long experience of vascular surgery and has been primarily involved in the development of several well-known medical devices, to include the first approved aortic endograft in the US (Ancure / Guidant) and, more recently, the Aptus EndoAnchor.  
Dr Deaton’s passion for innovation originates from the early 90’s when he became one of the few vascular surgeons involved in the pre-clinical development of the first bifurcated endograft introduced into clinical trials and he is a strong believer in interaction between surgeons and technical development. In this interview from the Veith Symposium in 2016, he explains his view on collaboration and development to improve treatment and patient outcome.

“I think that Endovab has very interesting technology that enables a variety of new treatment methods and opportunities for the aortic segment but also for other peripheral interventional techniques”, says Dr David Deaton.
David joins Endovab in the capacity of strategic clinical advisor and member of the board. “We are very happy to have Dr Deaton onboard with us, his experience, network, and insights to the American market are very valuable for us. This is particularly relevant now, as we are looking to expand the guidewire fixator technology to peripheral intervention, where the US is the dominating market.” Says Linus Bosaeus, CEO Endovab.



Senaste nyheter